市場調査レポート

商品コード

1423609

生殖毒性試験市場の2030年までの予測：製品別、方法別、技術別、エンドユーザー別、地域別の世界分析

Reproductive Toxicity Testing Market Forecasts to 2030 - Global Analysis By Product (Consumables, Assays and Equipment), Method (Cellular Assays, In-Silico Models, Biochemical Assays and Ex-Vivo Models), Technology, End User and By Geography

出版日: 2024年02月02日
発行: Stratistics Market Research Consulting
ページ情報: 英文 200+ Pages
納期: 2～3営業日

カスタマイズ可能

価格

PDF (Single User License)

USD 4,150 597,849円

レポートPDFを1名様のみがご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷は1回のみ可能です。印刷したもののご利用はPDFのご利用範囲に準拠します。

PDF (2-5 User License)

USD 5,250 756,315円

レポートPDFを同一事業所（所在地）内の5名までご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷は5回まで可能です。印刷したもののご利用はPDFのご利用範囲に準拠します。

PDF & Excel (Site License)

USD 6,350 914,781円

レポートPDFおよびExcelを同一事業所（所在地）内のすべての方にご利用頂けるライセンスです。PDFおよびExcel内のテキスト等のコピーは可能です。PDFおよびExcelの印刷は5回まで可能です。印刷したもののご利用はPDFおよびExcelのご利用範囲に準拠します。

PDF & Excel (Global Site License)

USD 7,500 1,080,450円

レポートPDFおよびExcelを企業内すべての方に使用頂けるライセンスです。PDFおよびExcel内のテキスト等のコピーは可能です。PDFおよびExcelの印刷は10回まで可能です。印刷したもののご利用はPDFおよびExcelのご利用範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=144.06円

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

Stratistics MRCによると、生殖毒性試験の世界市場は2023年に118億米ドルを占め、予測期間中にCAGR 11.4％で成長し、2030年には251億4,000万米ドルに達すると予測されています。

生殖毒性試験には、ヒトや動物の生殖器官に対する様々な物質の潜在的な悪影響を評価することが含まれます。生殖毒性の評価には、in vivo（動物実験）、in vitroアッセイ、計算モデル、ハイスループットスクリーニングなど、さまざまな調査手法が採用されます。評価には、生殖能力、胚発生、催奇形性、変異原性、ホルモン障害などのエンドポイントを評価することが含まれ、リスク評価と規制決定の指針となる重要なデータが提供されます。

ClinicalTrials.govによると、2020年8月現在、合計281,305件の試験がデータベースに登録されています。

検査技術の進歩

ハイスループット・スクリーニング、高度なin vitroアッセイ、予測計算モデルなど、現在進行中の技術革新は、毒性試験の分野に革命をもたらしています。これらの進歩により、試験の精度、効率、費用対効果が向上し、動物実験への依存度を減らしながら生殖毒性を総合的に評価できるようになった。さらに、より高感度で特異的な試験法の開発により、物質に対するヒトの反応をより的確に予測できるようになり、医薬品開発や製品安全性評価における意思決定が迅速化されます。その結果、化学、製薬、消費財産業で採用される頻度が高まり、市場拡大の原動力となります。

コストと時間の問題

包括的な生殖毒性試験を実施するには、特に長期的な評価と規制遵守のために、多額の費用と長い試験期間が必要となります。資源と時間の投資は、特に小規模の企業や研究機関にとっては法外なものとなり、大規模な試験を実施する能力に影響を与えます。経済的負担と長期のスケジュールは、これらの試験の普及を妨げ、包括的な生殖毒性評価へのアクセスを制限し、製品開発と規制承認プロセスのペースに影響を与える可能性があります。

拡大する製薬・化学産業

製薬・化学分野の継続的成長に伴い、新薬、化学物質、消費者製品の開発が増加しています。市場参入前にこれらの製品の安全性と規制コンプライアンスを確保するには、包括的な生殖毒性試験が必要です。このような徹底した安全性評価に対する需要の高まりは、試験サービス・プロバイダーが信頼性が高く効率的な試験サービスを提供する好機となっています。さらに、拡大する産業のニーズへの対応は、生殖毒性試験市場の成長を促進し、医薬品や化学物質の安全性評価の需要に応えることで、消費者により安全な製品を保証します。

規制上のハードル

地域によって多様で厳しい規制基準が、試験所やサービスプロバイダーに課題を突きつけています。コンプライアンスに対する要求が異なるため、統一された試験プロトコルの確立が複雑になり、製品の承認や市場参入が遅れる可能性があります。こうした多様な規制の枠組みとの交渉は複雑さを生み、生殖毒性試験サービスの効率とアクセシビリティに影響を与えます。

COVID-19の影響

COVID-19の流行は、サプライチェーンの混乱、研究所の閉鎖、研究の優先順位の変更により、生殖毒性試験の市場に悪影響を与えました。これらの要因により、生殖毒性試験の実施はより困難で時間がかかるものとなった。この最初の影響は、バイオテクノロジーと製薬部門が伝染病の流行中に経験した、より大きな困難の反映でした。しかし、時間が経過し、世界がパンデミックの課題に適応するにつれて、市場は堅調さを示し、持続的に拡大しました。

予測期間中、細胞培養技術分野が最大となる見込み

細胞培養技術分野が最大のシェアを占めると推定されます。細胞培養技術は、化学化合物や医薬品に対する細胞の反応を観察することで、毒性、遺伝毒性、その他の生殖エンドポイントの評価を可能にします。細胞培養ベースのアッセイは、生殖毒性に関する貴重な洞察を提供し、医薬品開発、安全性評価、規制遵守に役立ちます。さらに、細胞培養技術の進歩は精度、効率、予測能力を高め、生殖毒性試験手法の展望を形成し、この市場セグメントの成長に大きく寄与しています。

製薬・バイオテクノロジー企業セグメントは予測期間中最も高いCAGRが見込まれる

製薬・バイオテクノロジー企業セグメントは予測期間中に有利な成長を遂げると予測されています。製薬およびバイオテクノロジー企業は、生殖の健康への潜在的な悪影響を評価するために生殖毒性試験を広く利用しています。このような試験は、規制基準の遵守を保証し、医薬品の安全性プロファイルを強化し、医薬品開発段階において十分な情報に基づいた意思決定を支援します。さらに、これらの企業は、包括的かつ専門的な生殖毒性試験サービスの需要を促進し、世界の消費者のために自社製品の安全性と有効性を優先しながら市場を形成する上で重要な役割を果たしています。

最大のシェアを占める地域

アジア太平洋地域は、厳しい規制の枠組み、生殖に関する健康意識の高まり、試験手法の技術的進歩により、予測期間中最大の市場シェアを占めました。さらに、共同研究の増加や医薬品安全性評価への注目の高まりが、市場の需要をさらに押し上げています。アジア太平洋地域の製薬業界の発展と政府の支援策により、アジア太平洋地域は生殖毒性試験サービスのハブとして位置づけられており、競合の激化と技術革新がその業界情勢を形成しています。

CAGRが最も高い地域：

北米は、厳しい規制の枠組みと医薬品の安全性への関心の高まりにより、予測期間中に収益性の高い成長を遂げることが期待されます。この地域、特に米国とカナダにおける堅調な製薬・バイオテクノロジー産業が、生殖毒性試験サービスの需要を牽引しています。さらに、研究機関と業界プレイヤーの共同研究が試験手法の進歩にさらに貢献しており、北米は生殖毒性試験サービスと医薬品セクターの技術革新の極めて重要な拠点として位置づけられています。

無料のカスタマイズサービス

本レポートをご購読のお客様には、以下の無料カスタマイズオプションのいずれかをご利用いただけます：

企業プロファイル
- 追加市場プレイヤーの包括的プロファイリング（3社まで）
- 主要企業のSWOT分析（3社まで）
地域セグメンテーション
- 顧客の関心に応じた主要国の市場推計・予測・CAGR（注：フィージビリティチェックによる）
競合ベンチマーキング
- 製品ポートフォリオ、地理的プレゼンス、戦略的提携に基づく主要企業のベンチマーキング

北米
- 米国
- カナダ
- メキシコ
欧州
- ドイツ
- 英国
- イタリア
- フランス
- スペイン
- その他欧州
アジア太平洋地域
- 日本
- 中国
- インド
- オーストラリア
- ニュージーランド
- 韓国
- その他アジア太平洋地域
南米
- アルゼンチン
- ブラジル
- チリ
- その他南米
中東とアフリカ
- サウジアラビア
- アラブ首長国連邦
- カタール
- 南アフリカ
- その他中東とアフリカ

第10章主な発展

契約、パートナーシップ、コラボレーション、合弁事業
買収と合併
新製品の発売
事業拡大
その他の主要戦略

第11章企業プロファイル

Thermo Fisher Scientific
Laboratory Corporation of America Holdings
Charles River Laboratories International
Eurofins Scientific
Syngene International Limited
Jubilant Life Sciences Limited
Gentronix Ltd
Creative Bioarray
Inotiv Inc
MB Research Laboratories
Catalent, Inc.
Bio-Rad Laboratories
Evotec
QIAGEN
Promega Corporation

図表

List of Tables

Table 1 Global Reproductive Toxicity Testing Market Outlook, By Region (2021-2030) ($MN)
Table 2 Global Reproductive Toxicity Testing Market Outlook, By Product (2021-2030) ($MN)
Table 3 Global Reproductive Toxicity Testing Market Outlook, By Consumables (2021-2030) ($MN)
Table 4 Global Reproductive Toxicity Testing Market Outlook, By Assays (2021-2030) ($MN)
Table 5 Global Reproductive Toxicity Testing Market Outlook, By Bacterial Toxicity Assays (2021-2030) ($MN)
Table 6 Global Reproductive Toxicity Testing Market Outlook, By Bacterial Toxicity Assays (2021-2030) ($MN)
Table 7 Global Reproductive Toxicity Testing Market Outlook, By Receptor-Binding Assays (2021-2030) ($MN)
Table 8 Global Reproductive Toxicity Testing Market Outlook, By Cell-Based ELISA & Western Blot (2021-2030) ($MN)
Table 9 Global Reproductive Toxicity Testing Market Outlook, By Tissue Culture Assays (2021-2030) ($MN)
Table 10 Global Reproductive Toxicity Testing Market Outlook, By Equipment (2021-2030) ($MN)
Table 11 Global Reproductive Toxicity Testing Market Outlook, By Method (2021-2030) ($MN)
Table 12 Global Reproductive Toxicity Testing Market Outlook, By Cellular Assays (2021-2030) ($MN)
Table 13 Global Reproductive Toxicity Testing Market Outlook, By In-Silico Models (2021-2030) ($MN)
Table 14 Global Reproductive Toxicity Testing Market Outlook, By Biochemical Assays (2021-2030) ($MN)
Table 15 Global Reproductive Toxicity Testing Market Outlook, By Ex-Vivo Models (2021-2030) ($MN)
Table 16 Global Reproductive Toxicity Testing Market Outlook, By Technology (2021-2030) ($MN)
Table 17 Global Reproductive Toxicity Testing Market Outlook, By Cell Culture Technology (2021-2030) ($MN)
Table 18 Global Reproductive Toxicity Testing Market Outlook, By Toxicogenomics (2021-2030) ($MN)
Table 19 Global Reproductive Toxicity Testing Market Outlook, By High-Throughput Technology (2021-2030) ($MN)
Table 20 Global Reproductive Toxicity Testing Market Outlook, By End User (2021-2030) ($MN)
Table 21 Global Reproductive Toxicity Testing Market Outlook, By Academic and Research Institutes (2021-2030) ($MN)
Table 22 Global Reproductive Toxicity Testing Market Outlook, By Contract Research Organizations (2021-2030) ($MN)
Table 23 Global Reproductive Toxicity Testing Market Outlook, By Pharmaceutical and Biotechnology Companies (2021-2030) ($MN)
Table 24 Global Reproductive Toxicity Testing Market Outlook, By Other End Users (2021-2030) ($MN)
Table 25 North America Reproductive Toxicity Testing Market Outlook, By Country (2021-2030) ($MN)
Table 26 North America Reproductive Toxicity Testing Market Outlook, By Product (2021-2030) ($MN)
Table 27 North America Reproductive Toxicity Testing Market Outlook, By Consumables (2021-2030) ($MN)
Table 28 North America Reproductive Toxicity Testing Market Outlook, By Assays (2021-2030) ($MN)
Table 29 North America Reproductive Toxicity Testing Market Outlook, By Bacterial Toxicity Assays (2021-2030) ($MN)
Table 30 North America Reproductive Toxicity Testing Market Outlook, By Bacterial Toxicity Assays (2021-2030) ($MN)
Table 31 North America Reproductive Toxicity Testing Market Outlook, By Receptor-Binding Assays (2021-2030) ($MN)
Table 32 North America Reproductive Toxicity Testing Market Outlook, By Cell-Based ELISA & Western Blot (2021-2030) ($MN)
Table 33 North America Reproductive Toxicity Testing Market Outlook, By Tissue Culture Assays (2021-2030) ($MN)
Table 34 North America Reproductive Toxicity Testing Market Outlook, By Equipment (2021-2030) ($MN)
Table 35 North America Reproductive Toxicity Testing Market Outlook, By Method (2021-2030) ($MN)
Table 36 North America Reproductive Toxicity Testing Market Outlook, By Cellular Assays (2021-2030) ($MN)
Table 37 North America Reproductive Toxicity Testing Market Outlook, By In-Silico Models (2021-2030) ($MN)
Table 38 North America Reproductive Toxicity Testing Market Outlook, By Biochemical Assays (2021-2030) ($MN)
Table 39 North America Reproductive Toxicity Testing Market Outlook, By Ex-Vivo Models (2021-2030) ($MN)
Table 40 North America Reproductive Toxicity Testing Market Outlook, By Technology (2021-2030) ($MN)
Table 41 North America Reproductive Toxicity Testing Market Outlook, By Cell Culture Technology (2021-2030) ($MN)
Table 42 North America Reproductive Toxicity Testing Market Outlook, By Toxicogenomics (2021-2030) ($MN)
Table 43 North America Reproductive Toxicity Testing Market Outlook, By High-Throughput Technology (2021-2030) ($MN)
Table 44 North America Reproductive Toxicity Testing Market Outlook, By End User (2021-2030) ($MN)
Table 45 North America Reproductive Toxicity Testing Market Outlook, By Academic and Research Institutes (2021-2030) ($MN)
Table 46 North America Reproductive Toxicity Testing Market Outlook, By Contract Research Organizations (2021-2030) ($MN)
Table 47 North America Reproductive Toxicity Testing Market Outlook, By Pharmaceutical and Biotechnology Companies (2021-2030) ($MN)
Table 48 North America Reproductive Toxicity Testing Market Outlook, By Other End Users (2021-2030) ($MN)
Table 49 Europe Reproductive Toxicity Testing Market Outlook, By Country (2021-2030) ($MN)
Table 50 Europe Reproductive Toxicity Testing Market Outlook, By Product (2021-2030) ($MN)
Table 51 Europe Reproductive Toxicity Testing Market Outlook, By Consumables (2021-2030) ($MN)
Table 52 Europe Reproductive Toxicity Testing Market Outlook, By Assays (2021-2030) ($MN)
Table 53 Europe Reproductive Toxicity Testing Market Outlook, By Bacterial Toxicity Assays (2021-2030) ($MN)
Table 54 Europe Reproductive Toxicity Testing Market Outlook, By Bacterial Toxicity Assays (2021-2030) ($MN)
Table 55 Europe Reproductive Toxicity Testing Market Outlook, By Receptor-Binding Assays (2021-2030) ($MN)
Table 56 Europe Reproductive Toxicity Testing Market Outlook, By Cell-Based ELISA & Western Blot (2021-2030) ($MN)
Table 57 Europe Reproductive Toxicity Testing Market Outlook, By Tissue Culture Assays (2021-2030) ($MN)
Table 58 Europe Reproductive Toxicity Testing Market Outlook, By Equipment (2021-2030) ($MN)
Table 59 Europe Reproductive Toxicity Testing Market Outlook, By Method (2021-2030) ($MN)
Table 60 Europe Reproductive Toxicity Testing Market Outlook, By Cellular Assays (2021-2030) ($MN)
Table 61 Europe Reproductive Toxicity Testing Market Outlook, By In-Silico Models (2021-2030) ($MN)
Table 62 Europe Reproductive Toxicity Testing Market Outlook, By Biochemical Assays (2021-2030) ($MN)
Table 63 Europe Reproductive Toxicity Testing Market Outlook, By Ex-Vivo Models (2021-2030) ($MN)
Table 64 Europe Reproductive Toxicity Testing Market Outlook, By Technology (2021-2030) ($MN)
Table 65 Europe Reproductive Toxicity Testing Market Outlook, By Cell Culture Technology (2021-2030) ($MN)
Table 66 Europe Reproductive Toxicity Testing Market Outlook, By Toxicogenomics (2021-2030) ($MN)
Table 67 Europe Reproductive Toxicity Testing Market Outlook, By High-Throughput Technology (2021-2030) ($MN)
Table 68 Europe Reproductive Toxicity Testing Market Outlook, By End User (2021-2030) ($MN)
Table 69 Europe Reproductive Toxicity Testing Market Outlook, By Academic and Research Institutes (2021-2030) ($MN)
Table 70 Europe Reproductive Toxicity Testing Market Outlook, By Contract Research Organizations (2021-2030) ($MN)
Table 71 Europe Reproductive Toxicity Testing Market Outlook, By Pharmaceutical and Biotechnology Companies (2021-2030) ($MN)
Table 72 Europe Reproductive Toxicity Testing Market Outlook, By Other End Users (2021-2030) ($MN)
Table 73 Asia Pacific Reproductive Toxicity Testing Market Outlook, By Country (2021-2030) ($MN)
Table 74 Asia Pacific Reproductive Toxicity Testing Market Outlook, By Product (2021-2030) ($MN)
Table 75 Asia Pacific Reproductive Toxicity Testing Market Outlook, By Consumables (2021-2030) ($MN)
Table 76 Asia Pacific Reproductive Toxicity Testing Market Outlook, By Assays (2021-2030) ($MN)
Table 77 Asia Pacific Reproductive Toxicity Testing Market Outlook, By Bacterial Toxicity Assays (2021-2030) ($MN)
Table 78 Asia Pacific Reproductive Toxicity Testing Market Outlook, By Bacterial Toxicity Assays (2021-2030) ($MN)
Table 79 Asia Pacific Reproductive Toxicity Testing Market Outlook, By Receptor-Binding Assays (2021-2030) ($MN)
Table 80 Asia Pacific Reproductive Toxicity Testing Market Outlook, By Cell-Based ELISA & Western Blot (2021-2030) ($MN)
Table 81 Asia Pacific Reproductive Toxicity Testing Market Outlook, By Tissue Culture Assays (2021-2030) ($MN)
Table 82 Asia Pacific Reproductive Toxicity Testing Market Outlook, By Equipment (2021-2030) ($MN)
Table 83 Asia Pacific Reproductive Toxicity Testing Market Outlook, By Method (2021-2030) ($MN)
Table 84 Asia Pacific Reproductive Toxicity Testing Market Outlook, By Cellular Assays (2021-2030) ($MN)
Table 85 Asia Pacific Reproductive Toxicity Testing Market Outlook, By In-Silico Models (2021-2030) ($MN)
Table 86 Asia Pacific Reproductive Toxicity Testing Market Outlook, By Biochemical Assays (2021-2030) ($MN)
Table 87 Asia Pacific Reproductive Toxicity Testing Market Outlook, By Ex-Vivo Models (2021-2030) ($MN)
Table 88 Asia Pacific Reproductive Toxicity Testing Market Outlook, By Technology (2021-2030) ($MN)
Table 89 Asia Pacific Reproductive Toxicity Testing Market Outlook, By Cell Culture Technology (2021-2030) ($MN)
Table 90 Asia Pacific Reproductive Toxicity Testing Market Outlook, By Toxicogenomics (2021-2030) ($MN)
Table 91 Asia Pacific Reproductive Toxicity Testing Market Outlook, By High-Throughput Technology (2021-2030) ($MN)
Table 92 Asia Pacific Reproductive Toxicity Testing Market Outlook, By End User (2021-2030) ($MN)
Table 93 Asia Pacific Reproductive Toxicity Testing Market Outlook, By Academic and Research Institutes (2021-2030) ($MN)
Table 94 Asia Pacific Reproductive Toxicity Testing Market Outlook, By Contract Research Organizations (2021-2030) ($MN)
Table 95 Asia Pacific Reproductive Toxicity Testing Market Outlook, By Pharmaceutical and Biotechnology Companies (2021-2030) ($MN)
Table 96 Asia Pacific Reproductive Toxicity Testing Market Outlook, By Other End Users (2021-2030) ($MN)
Table 97 South America Reproductive Toxicity Testing Market Outlook, By Country (2021-2030) ($MN)
Table 98 South America Reproductive Toxicity Testing Market Outlook, By Product (2021-2030) ($MN)
Table 99 South America Reproductive Toxicity Testing Market Outlook, By Consumables (2021-2030) ($MN)
Table 100 South America Reproductive Toxicity Testing Market Outlook, By Assays (2021-2030) ($MN)
Table 101 South America Reproductive Toxicity Testing Market Outlook, By Bacterial Toxicity Assays (2021-2030) ($MN)
Table 102 South America Reproductive Toxicity Testing Market Outlook, By Bacterial Toxicity Assays (2021-2030) ($MN)
Table 103 South America Reproductive Toxicity Testing Market Outlook, By Receptor-Binding Assays (2021-2030) ($MN)
Table 104 South America Reproductive Toxicity Testing Market Outlook, By Cell-Based ELISA & Western Blot (2021-2030) ($MN)
Table 105 South America Reproductive Toxicity Testing Market Outlook, By Tissue Culture Assays (2021-2030) ($MN)
Table 106 South America Reproductive Toxicity Testing Market Outlook, By Equipment (2021-2030) ($MN)
Table 107 South America Reproductive Toxicity Testing Market Outlook, By Method (2021-2030) ($MN)
Table 108 South America Reproductive Toxicity Testing Market Outlook, By Cellular Assays (2021-2030) ($MN)
Table 109 South America Reproductive Toxicity Testing Market Outlook, By In-Silico Models (2021-2030) ($MN)
Table 110 South America Reproductive Toxicity Testing Market Outlook, By Biochemical Assays (2021-2030) ($MN)
Table 111 South America Reproductive Toxicity Testing Market Outlook, By Ex-Vivo Models (2021-2030) ($MN)
Table 112 South America Reproductive Toxicity Testing Market Outlook, By Technology (2021-2030) ($MN)
Table 113 South America Reproductive Toxicity Testing Market Outlook, By Cell Culture Technology (2021-2030) ($MN)
Table 114 South America Reproductive Toxicity Testing Market Outlook, By Toxicogenomics (2021-2030) ($MN)
Table 115 South America Reproductive Toxicity Testing Market Outlook, By High-Throughput Technology (2021-2030) ($MN)
Table 116 South America Reproductive Toxicity Testing Market Outlook, By End User (2021-2030) ($MN)
Table 117 South America Reproductive Toxicity Testing Market Outlook, By Academic and Research Institutes (2021-2030) ($MN)
Table 118 South America Reproductive Toxicity Testing Market Outlook, By Contract Research Organizations (2021-2030) ($MN)
Table 119 South America Reproductive Toxicity Testing Market Outlook, By Pharmaceutical and Biotechnology Companies (2021-2030) ($MN)
Table 120 South America Reproductive Toxicity Testing Market Outlook, By Other End Users (2021-2030) ($MN)
Table 121 Middle East & Africa Reproductive Toxicity Testing Market Outlook, By Country (2021-2030) ($MN)
Table 122 Middle East & Africa Reproductive Toxicity Testing Market Outlook, By Product (2021-2030) ($MN)
Table 123 Middle East & Africa Reproductive Toxicity Testing Market Outlook, By Consumables (2021-2030) ($MN)
Table 124 Middle East & Africa Reproductive Toxicity Testing Market Outlook, By Assays (2021-2030) ($MN)
Table 125 Middle East & Africa Reproductive Toxicity Testing Market Outlook, By Bacterial Toxicity Assays (2021-2030) ($MN)
Table 126 Middle East & Africa Reproductive Toxicity Testing Market Outlook, By Bacterial Toxicity Assays (2021-2030) ($MN)
Table 127 Middle East & Africa Reproductive Toxicity Testing Market Outlook, By Receptor-Binding Assays (2021-2030) ($MN)
Table 128 Middle East & Africa Reproductive Toxicity Testing Market Outlook, By Cell-Based ELISA & Western Blot (2021-2030) ($MN)
Table 129 Middle East & Africa Reproductive Toxicity Testing Market Outlook, By Tissue Culture Assays (2021-2030) ($MN)
Table 130 Middle East & Africa Reproductive Toxicity Testing Market Outlook, By Equipment (2021-2030) ($MN)
Table 131 Middle East & Africa Reproductive Toxicity Testing Market Outlook, By Method (2021-2030) ($MN)
Table 132 Middle East & Africa Reproductive Toxicity Testing Market Outlook, By Cellular Assays (2021-2030) ($MN)
Table 133 Middle East & Africa Reproductive Toxicity Testing Market Outlook, By In-Silico Models (2021-2030) ($MN)
Table 134 Middle East & Africa Reproductive Toxicity Testing Market Outlook, By Biochemical Assays (2021-2030) ($MN)
Table 135 Middle East & Africa Reproductive Toxicity Testing Market Outlook, By Ex-Vivo Models (2021-2030) ($MN)
Table 136 Middle East & Africa Reproductive Toxicity Testing Market Outlook, By Technology (2021-2030) ($MN)
Table 137 Middle East & Africa Reproductive Toxicity Testing Market Outlook, By Cell Culture Technology (2021-2030) ($MN)
Table 138 Middle East & Africa Reproductive Toxicity Testing Market Outlook, By Toxicogenomics (2021-2030) ($MN)
Table 139 Middle East & Africa Reproductive Toxicity Testing Market Outlook, By High-Throughput Technology (2021-2030) ($MN)
Table 140 Middle East & Africa Reproductive Toxicity Testing Market Outlook, By End User (2021-2030) ($MN)
Table 141 Middle East & Africa Reproductive Toxicity Testing Market Outlook, By Academic and Research Institutes (2021-2030) ($MN)
Table 142 Middle East & Africa Reproductive Toxicity Testing Market Outlook, By Contract Research Organizations (2021-2030) ($MN)
Table 143 Middle East & Africa Reproductive Toxicity Testing Market Outlook, By Pharmaceutical and Biotechnology Companies (2021-2030) ($MN)
Table 144 Middle East & Africa Reproductive Toxicity Testing Market Outlook, By Other End Users (2021-2030) ($MN)

Product Code: SMRC24843

According to Stratistics MRC, the Global Reproductive Toxicity Testing Market is accounted for $11.80 billion in 2023 and is expected to reach $25.14 billion by 2030 growing at a CAGR of 11.4% during the forecast period. Reproductive toxicity testing involves assessing the potential adverse effects of various substances on the reproductive systems of humans or animals. Various testing methodologies, including in vivo (animal testing), in vitro assays, computational models, and high-throughput screening, are employed to assess reproductive toxicity. The assessments encompass evaluating endpoints such as fertility, embryonic development, teratogenicity, mutagenicity, and hormonal disruptions, providing essential data to guide risk assessment and regulatory decisions.

According to the ClinicalTrials.gov, a total of 281,305 studies are registered on their database as of August 2020.

Market Dynamics:

Driver:

Advancements in testing technologies

Ongoing innovations, such as high-throughput screening, sophisticated in vitro assays, and predictive computational models, revolutionise the field of toxicity testing. These advancements enhance testing accuracy, efficiency, and cost-effectiveness, allowing for comprehensive evaluation of reproductive toxicity with reduced reliance on animal testing. Furthermore, the development of more sensitive and specific testing methods enables better prediction of human responses to substances, expediting decision-making in drug development and product safety assessments. Consequently, the chemical, pharmaceutical, and consumer goods industries will employ it more frequently, driving market expansion.

Restraint:

Cost and time intensiveness

Conducting comprehensive reproductive toxicity studies involves substantial expenses and lengthy testing periods, especially for long-term assessments and regulatory compliance. The investment of resources and time can be prohibitive, particularly for smaller companies or research institutions, impacting their ability to conduct extensive testing. The financial burden and extended timelines hinder widespread adoption of these tests, potentially limiting access to comprehensive reproductive toxicity evaluations and affecting the pace of product development and regulatory approval processes.

Opportunity:

Expanding Pharmaceutical and Chemical Industries

With continuous growth in the pharmaceutical and chemical sectors, there's been an increased development of new drugs, chemicals, and consumer products. Ensuring the safety and regulatory compliance of these products before market entry necessitates comprehensive reproductive toxicity testing. This rising demand for thorough safety assessments presents an opportunity for testing service providers to offer reliable and efficient testing services. Moreover, addressing the needs of expanding industries fuels the growth of the reproductive toxicity testing market, catering to the demand for safety evaluations in pharmaceuticals and chemicals, thus ensuring safer products for consumers.

Threat:

Regulatory hurdles

Diverse and stringent regulatory standards across regions pose challenges for testing laboratories and service providers. Varying compliance demands complicate the establishment of uniform testing protocols, potentially delaying product approvals and market entry. Negotiating these diverse regulatory frameworks creates complexity, impacting the efficiency and accessibility of reproductive toxicity testing services.

Covid-19 Impact

The COVID-19 pandemic had a detrimental impact on the market for reproductive toxicity testing due to supply chain disruptions, laboratory closures, and a change in research priorities. These factors made reproductive toxicity testing more difficult and time-consuming to perform. This initial effect was a reflection of the larger difficulties that the biotechnology and pharmaceutical sectors experienced during the epidemic. However, the market demonstrated robustness and sustained expansion as time passed and the world adjusted to the pandemic's challenges.

The cell culture technology segment is expected to be the largest during the forecast period

The cell culture technology segment is estimated to hold the largest share. Cell culture technology allows for the evaluation of toxicity, genotoxicity, and other reproductive endpoints by observing cellular responses to chemical compounds or pharmaceuticals. Cell culture-based assays provide valuable insights into reproductive toxicity, aiding in drug development, safety assessment, and regulatory compliance. Moreover, advancements in cell culture techniques enhance accuracy, efficiency, and predictive capabilities, shaping the landscape of reproductive toxicity testing methodologies and contributing significantly to this market segment's growth.

The pharmaceutical and biotechnology companies segment is expected to have the highest CAGR during the forecast period

The pharmaceutical and biotechnology companies segment is anticipated to have lucrative growth during the forecast period. Pharmaceutical and biotechnology companies extensively utilise reproductive toxicity testing to assess potential adverse effects on reproductive health. Such testing ensures compliance with regulatory standards, enhances drug safety profiles, and aids in making informed decisions during drug development stages. Moreover, these companies drive the demand for comprehensive and specialised reproductive toxicity testing services, playing a critical role in shaping the market while prioritising the safety and efficacy of their products for global consumers.

Region with largest share:

Asia Pacific commanded the largest market share during the extrapolated period owing to its stringent regulatory frameworks, rising awareness of reproductive health, and technological advancements in testing methodologies. Furthermore, growing research collaborations and a burgeoning focus on drug safety assessment further propel market demand. The region's evolving pharmaceutical industry, coupled with supportive government initiatives, positions the Asia-Pacific as a hub for reproductive toxicity testing services, with heightened competition and innovation shaping its landscape.

Region with highest CAGR:

North America is expected to witness profitable growth over the projection period, due to stringent regulatory frameworks and a heightened focus on pharmaceutical safety. The region's robust pharmaceutical and biotechnology industries, particularly in the United States and Canada, drive the demand for reproductive toxicity testing services. Furthermore, collaborations between research institutions and industry players further contribute to advancements in testing methodologies, positioning North America as a pivotal hub for reproductive toxicity testing services and innovations in the pharmaceutical sector.

Key players in the market

Some of the key players in the Reproductive Toxicity Testing Market include Thermo Fisher Scientific, Laboratory Corporation of America Holdings, Charles River Laboratories International, Eurofins Scientific, Syngene International Limited, Jubilant Life Sciences Limited, Gentronix Ltd, Creative Bioarray, Inotiv Inc, MB Research Laboratories, Catalent, Inc., Bio-Rad Laboratories, Evotec, QIAGEN and Promega Corporation.

Key Developments:

In May 2023, Wheeler Bio, a CDMO, collaborated with Charles River Labs to utilize RightSource, a flexible biologic testing lab, at its Oklahoma City facility. This partnership aimed to enhance Wheeler Bio's quality control without the need to establish its own lab, ultimately benefiting its biologic products and potential clients.

In October 2022, Thermo Fisher Scientific Inc. declared that it had expanded its laboratory operations in Highland Heights, Kentucky, to assist customers in delivering personalized medications to patients. The existing facility, which included central laboratory and biomarker operations, provided biopharma customers with high-quality laboratory services to accelerate drug development. This move increased the company's clinical diagnostics business worldwide and enhanced its global presence across the business space.

Products Covered:

Consumables
Assays
Equipment

Methods Covered:

Cellular Assays
In-Silico Models
Biochemical Assays
Ex-Vivo Models

Technologies Covered:

Cell Culture Technology
Toxicogenomics
High-Throughput Technology

End Users Covered:

Academic and Research Institutes
Contract Research Organizations
Pharmaceutical and Biotechnology Companies
Other End Users

Regions Covered:

North America
- US
- Canada
- Mexico
Europe
- Germany
- UK
- Italy
- France
- Spain
- Rest of Europe
Asia Pacific
- Japan
- China
- India
- Australia
- New Zealand
- South Korea
- Rest of Asia Pacific
South America
- Argentina
- Brazil
- Chile
- Rest of South America
Middle East & Africa
- Saudi Arabia
- UAE
- Qatar
- South Africa
- Rest of Middle East & Africa

What our report offers:

Market share assessments for the regional and country-level segments
Strategic recommendations for the new entrants
Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
Strategic recommendations in key business segments based on the market estimations
Competitive landscaping mapping the key common trends
Company profiling with detailed strategies, financials, and recent developments
Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

Company Profiling
- Comprehensive profiling of additional market players (up to 3)
- SWOT Analysis of key players (up to 3)
Regional Segmentation
- Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
Competitive Benchmarking
- Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

1 Executive Summary

2 Preface

2.1 Abstract
2.2 Stake Holders
2.3 Research Scope
2.4 Research Methodology
- 2.4.1 Data Mining
- 2.4.2 Data Analysis
- 2.4.3 Data Validation
- 2.4.4 Research Approach
2.5 Research Sources
- 2.5.1 Primary Research Sources
- 2.5.2 Secondary Research Sources
- 2.5.3 Assumptions

3 Market Trend Analysis

3.1 Introduction
3.2 Drivers
3.3 Restraints
3.4 Opportunities
3.5 Threats
3.6 Product Analysis
3.7 Technology Analysis
3.8 End User Analysis
3.9 Emerging Markets
3.10 Impact of Covid-19

4 Porters Five Force Analysis

4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry

5 Global Reproductive Toxicity Testing Market, By Product

5.1 Introduction
5.2 Consumables
5.3 Assays
- 5.3.1 Bacterial Toxicity Assays
- 5.3.2 Bacterial Toxicity Assays
- 5.3.3 Receptor-Binding Assays
- 5.3.4 Cell-Based ELISA & Western Blot
- 5.3.5 Tissue Culture Assays
5.4 Equipment

6 Global Reproductive Toxicity Testing Market, By Method

6.1 Introduction
6.2 Cellular Assays
6.3 In-Silico Models
6.4 Biochemical Assays
6.5 Ex-Vivo Models

7 Global Reproductive Toxicity Testing Market, By Technology

7.1 Introduction
7.2 Cell Culture Technology
7.3 Toxicogenomics
7.4 High-Throughput Technology

8 Global Reproductive Toxicity Testing Market, By End User

8.1 Introduction
8.2 Academic and Research Institutes
8.3 Contract Research Organizations
8.4 Pharmaceutical and Biotechnology Companies
8.5 Other End Users

9 Global Reproductive Toxicity Testing Market, By Geography

9.1 Introduction
9.2 North America
- 9.2.1 US
- 9.2.2 Canada
- 9.2.3 Mexico
9.3 Europe
- 9.3.1 Germany
- 9.3.2 UK
- 9.3.3 Italy
- 9.3.4 France
- 9.3.5 Spain
- 9.3.6 Rest of Europe
9.4 Asia Pacific
- 9.4.1 Japan
- 9.4.2 China
- 9.4.3 India
- 9.4.4 Australia
- 9.4.5 New Zealand
- 9.4.6 South Korea
- 9.4.7 Rest of Asia Pacific
9.5 South America
- 9.5.1 Argentina
- 9.5.2 Brazil
- 9.5.3 Chile
- 9.5.4 Rest of South America
9.6 Middle East & Africa
- 9.6.1 Saudi Arabia
- 9.6.2 UAE
- 9.6.3 Qatar
- 9.6.4 South Africa
- 9.6.5 Rest of Middle East & Africa

10 Key Developments

10.1 Agreements, Partnerships, Collaborations and Joint Ventures
10.2 Acquisitions & Mergers
10.3 New Product Launch
10.4 Expansions
10.5 Other Key Strategies

11 Company Profiling

11.1 Thermo Fisher Scientific
11.2 Laboratory Corporation of America Holdings
11.3 Charles River Laboratories International
11.4 Eurofins Scientific
11.5 Syngene International Limited
11.6 Jubilant Life Sciences Limited
11.7 Gentronix Ltd
11.8 Creative Bioarray
11.9 Inotiv Inc
11.10 MB Research Laboratories
11.11 Catalent, Inc.
11.12 Bio-Rad Laboratories
11.13 Evotec
11.14 QIAGEN
11.15 Promega Corporation

生殖毒性試験市場の2030年までの予測：製品別、方法別、技術別、エンドユーザー別、地域別の世界分析

Reproductive Toxicity Testing Market Forecasts to 2030 - Global Analysis By Product (Consumables, Assays and Equipment), Method (Cellular Assays, In-Silico Models, Biochemical Assays and Ex-Vivo Models), Technology, End User and By Geography

最大のシェアを占める地域

CAGRが最も高い地域：

無料のカスタマイズサービス

本レポートをご購読のお客様には、以下の無料カスタマイズオプションのいずれかをご利用いただけます：

目次

第1章 エグゼクティブサマリー

第2章 序文

第3章 市場動向分析

第4章 ポーターのファイブフォース分析

第5章 世界の生殖毒性試験市場：製品別

第6章 世界の生殖毒性試験市場：方法別

第7章 世界の生殖毒性試験市場：技術別

第8章 世界の生殖毒性試験市場：エンドユーザー別

第9章 世界の生殖毒性試験市場：地域別

第10章 主な発展

第11章 企業プロファイル